Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

Kasuya,Kazuhiko; Nagakawa,Yuichi; Suzuki,Minako; Suzuki,Yoshiaki; Kyo,Bunso; Suzuki,Satoru; Matsudo,Takaaki; Itoi,Takao; Tsuchida,Akihiko; Aoki,Tatsuya

doi:10.3892/etm.2012.456

April 2012 Volume 3 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April 2012 Volume 3 Issue 4

Full Size Image

Article Open Access

Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

Authors:
- Kazuhiko Kasuya
- Yuichi Nagakawa
- Minako Suzuki
- Yoshiaki Suzuki
- Bunso Kyo
- Satoru Suzuki
- Takaaki Matsudo
- Takao Itoi
- Akihiko Tsuchida
- Tatsuya Aoki
View Affiliations / Copyright

Affiliations: Department of Digestive Surgery, Tokyo Medical University, Tokyo, Japan
Pages: 599-602
|
Published online on: January 18, 2012

https://doi.org/10.3892/etm.2012.456
Expand metrics +

Abstract

We previously reported that the administration of bevacizumab for pancreatic neuroendocrine tumors inhibited angiogenesis in the host, resulting in tumor growth inhibition. In light of these results, we compared the effect of bevacizumab/gemcitabine/S-1 combination therapy vs. bevacizumab monotherapy. The QGP-1 pancreatic neuroendocrine carcinoma cell line and the BxPC-3 ductal cell carcinoma cell line were transplanted into the subcutaneous tissue of mice, and the mice were treated for 3 weeks with bevacizumab [50 mg/kg intraperitoneally (i.p.) twice weekly], gemcitabine (240 mg/kg i.p. once weekly) and S-1 (10 mg/kg orally five times weekly). The antitumor effect and side effects were evaluated by measuring the tumor volume and weight and by changes in body weight, respectively. The tumor volume became smaller (from the maximum volume) in the group treated with bevacizumab, gemcitabine and S-1 (BGS) and the group treated with bevacizumab and gemcitabine (BG). A significant difference was noted in the tumor weight between the BG group and the group treated with bevacizumab alone. A relatively significant decrease in the body weight was observed in the BGS and BG groups. We conclude that gemcitabine is appropriate as a drug used in combination with bevacizumab for pancreatic neuroendocrine tumors.

View Figures

View References

1.	Eriksson B and Oberg K: Neuroendocrine tumours of the pancreas. Br J Surg. 87:129–131. 2000. View Article : Google Scholar
2.	Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, et al: Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res. 13:187–196. 2007. View Article : Google Scholar
3.	Miljković MD, Girotra M, Abraham RR and Erlich RB: Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci. 57:9–18. 2011.PubMed/NCBI
4.	Jain RK, Duda DG, Clark JW and Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 3:24–40. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Kasuya K, Nagakawa Y, Suzuki M, Tanaka H, Ohta H, Itoi T and Tsuchida A: Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect. Exp Ther Med. 2:1047–1052. 2011.
6.	Grindey GB, Hertel LW and Plunkett W: Cytotoxicity and antitumor activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Invest. 8:313–318. 1990.
7.	Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar
8.	Georgieva I, Koychev D, Wang Y, Holstein J, Hopfenmüller W, Zeitz M and Grabowski P: ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology. 91:121–130. 2010. View Article : Google Scholar
9.	Shah DK, Veith J, Bernacki RJ and Balthasar JP: Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer. Cancer Chemother Pharmacol. 68:951–958. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G and Peters GJ: Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol. 4(Suppl 11): 42–46. 1995.PubMed/NCBI
11.	Fukushima M, Satake H, Uchida J, et al: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 13:693–698. 1998.PubMed/NCBI
12.	Nakahira S, Nakamori S, Tsujie M, et al: Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res. 28:179–186. 2008.PubMed/NCBI
13.	Yao JC, Phan A, Hoff PM, et al: Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase ll study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Clin Oncol. 26:1316–1323. 2008. View Article : Google Scholar
14.	Pour PM and Kazakoff K: Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Am J Pathol. 149:1017–1025. 1996.PubMed/NCBI
15.	Kindler HL, Niedzwiecki D, Hollis D, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 28:3617–3622. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Masellis AM, Sielaff TD and Bender GP: Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens. Int J Clin Oncol. 14:478–481. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Nakai Y, Isayama H, Sasaki T, et al: Impact of S-1 on the survival of patients with advanced pancreatic cancer. Pancreas. 39:989–993. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Ohge H and Sueda T: Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas. J Gastrointest Surg. 13:85–92. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Yamada Y, Yamaguchi T, Matsumoto H, et al: Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Invest New Drugs. Sept 6–2011.(E-pub ahead of print).
20.	Oberg K, Akerström G, Rindi G and Jelic S; ESMO Guidelines Working Group: Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5): v223–v227. 2010. View Article : Google Scholar
21.	Villaume K, Blanc M, Gouysse G, et al: VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology. 91:268–278. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles